泌尿器科領域におけるNeocarzinostatinに関する臨床的研究 第2報 : 末期尿路性器悪性腫瘍患者に対する臨床効果

Abstract

Neocarzinostatin was administrated to 9 patients with transitional cell cancer originated from the urinary bladder or the renal pelvis, and 6 patients with adenocarcinoma from the prostate. All patients had objective and measurable metastatic lesions such as 8 with palpable mass, 9 with bone metastasis demonstrable by bone scintigram, and 3 with pulmonary metastasis demonstrable by chest X-ray. Neocarzinostatin was administrated intravenously daily or twice a week with dosage ranging from I mg or 2 mg, and with total dosages ranging from 6 mg to 50 mg. Side effect was seen in 9 patients of digestive complaints, and 5 of thrombocytopenia. Neocarzinostatin demonstrated therapeutic effect in 2 patients (Kalnofsky: 1-C). Our results reveal the efficacy of Neocarzinostatin to advanced urogenital cancer.